Evidence map›Paper›PMID 33933156›Full record

ArticleBiology of sex differences2021

Sex differences in soluble prorenin receptor in patients with type 2 diabetes.

Bruna Visniauskas, Danielle Y Arita, Carla B Rosales, Mohammed A Feroz, Christina Luffman, Michael J Accavitti, Gabrielle Dawkins, Jennifer Hong, Andrew C Curnow, Tina K Thethi and 5 more

Open access · goldAbstract read
In one paragraph

Article in Biology of sex differences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Bruna Visniauskas *Department of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, SL39, New Orleans, LA, 70112, USA.
Danielle Y Arita *Department of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, SL39, New Orleans, LA, 70112, USA.
Carla B RosalesDepartment of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, SL39, New Orleans, LA, 70112, USA.
Mohammed A FerozDepartment of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, SL39, New Orleans, LA, 70112, USA.
Christina LuffmanDepartment of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, SL39, New Orleans, LA, 70112, USA.
Michael J AccavittiDepartment of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, SL39, New Orleans, LA, 70112, USA.
Gabrielle DawkinsDepartment of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, SL39, New Orleans, LA, 70112, USA.
Jennifer HongDepartment of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, SL39, New Orleans, LA, 70112, USA.
Andrew C CurnowDepartment of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, SL39, New Orleans, LA, 70112, USA.
Tina K ThethiDepartment of Medicine, Endocrinology Division, Tulane University School of Medicine, New Orleans, LA, USA.
John J LefanteDepartment of Biostatistics and Data Science, School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Edgar A JaimesRenal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Franck Mauvais-JarvisDepartment of Medicine, Endocrinology Division, Tulane University School of Medicine, New Orleans, LA, USA.
Vivian A FonsecaDepartment of Medicine, Endocrinology Division, Tulane University School of Medicine, New Orleans, LA, USA.
Minolfa C PrietoDepartment of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, SL39, New Orleans, LA, 70112, USA. mprieto@tulane.edu.ORCID http://orcid.org/0000-0002-0199-3193
Tulane University · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
National Dissemination of I-Corps@NCATS: Accelerating Translation through CommercializationUL1TR003096 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M, KIMBERLY, ROBERT P. · 2019 to 2023
$43.6M
Tulane Building Interdisciplinary Research Careers in Women's Health (BIRCWH)K12HD043451 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI KROUSEL-WOOD, MARIE · 2002 to 2023
$9.9M
Targeting the estrogen receptor-α to protect functional β-cell mass in womenR01DK074970 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI Franck Mauvais-Jarvis · 2007 to 2026
$6.0M
Translational Research in Hypertension and Renal BiologyP30GM103337 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI NAVAR, LUIS GABRIEL · 2012 to 2016
$5.8M
PLEIOTROPIC EFFECTS OF PRORENIN RECEPOR IN COLLECTING DUCT AND INTRARENAL RAS ACTIVATIONR01DK104375 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI PRIETO, MINOLFA C · 2014 to 2018
$1.7M
Repurposing estrogens to improve pancreatic islet transplantationR01DK107444 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI MAUVAIS-JARVIS, FRANCK · 2016 to 2019
$1.5M
Renal tubule-specific nanotherapeutics for acute kidney injuryR01DK114321 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN, JAIMES, EDGAR A · 2018 to 2020
$796k
BLRD VA I01 BX003725NCATS NIH HHS UL1 TR003096NCI NIH HHS P30 CA008748NICHD NIH HHS K12 HD043451NIDDK NIH HHS R01 DK074970NIDDK NIH HHS R01 DK104375NIDDK NIH HHS R01 DK107444NIDDK NIH HHS R01 DK114321NIDDK NIH HHS RO1-DK114321NIGMS NIH HHS P30 GM103337NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

backgroundThe soluble prorenin receptor (sPRR), a member of the renin-angiotensin system (RAS), is elevated in plasma of patients with preeclampsia, hypertension, chronic kidney disease (CKD), and type 2 diabetes. Our goal was to examine the relationship between sPRR and RAS activation to define whether sexual dimorphisms in sPRR might explain sex disparities in renal outcomes in patients with type 2 diabetes.

methodsTwo hundred sixty-nine participants were included in the study (mean age, 48 ± 16 years; 42% men, 58% women), including 173 controls and 96 subjects with type 2 diabetes. In plasma and urine, we measured sPRR, plasma renin activity (PRA), and prorenin. In the urine, we also measured angiotensinogen along with other biomarkers of renal dysfunction.

resultsPlasma sPRR and PRA were significantly higher in women with type 2 diabetes compared to men. In these women, plasma sPRR was positively correlated with PRA, age, and body mass index (BMI). In contrast, in men the sPRR in urine but not in plasma positively correlated with eGFR in urine, but negatively correlated with urine renin activity, plasma glucose, age, and BMI.

conclusionsIn patients with type 2 diabetes, sPRR contributes to RAS stimulation in a sex-dependent fashion. In diabetic women, increased plasma sPRR parallels the activation of systemic RAS; while in diabetic men, decreased sPRR in urine matches intrarenal RAS stimulation. sPRR might be a potential indicator of intrarenal RAS activation and renal dysfunction in men and women with type 2 diabetes.

Indexed as

Diabetes Mellitus, Type 2AdultFemaleHumansKidney DiseasesMaleMiddle AgedProrenin ReceptorReceptors, Cell SurfaceReninSex CharacteristicsProrenin ReceptorReceptors, Cell SurfaceRenineGFRPlasma renin activitySexual dimorphismUrine angiotensinogenUrine renin activity

Identifiers

PMID33933156
PMCPMC8088668
OpenAlexW3157598455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.